Research To Practice (RTP) is pleased to offer hospitals and cancer centers throughout the United States the opportunity to participate in an interactive live educational activity focused on the management of breast cancer. Each session in this regional series will feature a blend of didactic presentation, discussion of steering committee members’ treatment recommendations and follow-up audience Q&A.
If you are interested in hosting a session at your organization, please email our Meetings Department at Meetings@ResearchToPractice.com or call (800) 233-6153.
STEERING COMMITTEE
Adam M Brufsky, MD, PhD
Professor of Medicine
UPMC Hillman Cancer Center
Department of Medicine
University of Pittsburgh
Pittsburgh, Pennsylvania
Komal Jhaveri, MD, FACP, FASCO
Patricia and James Cayne Chair for Junior Faculty
Associate Attending Physician
Breast Medicine Service and Early Drug Development Service
Section Head, Endocrine Therapy Research Program
Clinical Director, Early Drug Development Service
Department of Medicine
Memorial Sloan Kettering Cancer Center
Associate Professor of Medicine
Weill Cornell College of Medicine
New York, New York
Kevin Kalinsky, MD, MS, FASCO
Professor of Medicine
Director, Division of Medical Oncology
Director, Glenn Family Breast Center
Winship Cancer Institute at Emory University
Atlanta, Georgia
Reshma L Mahtani, DO
Chief of Breast Medical Oncology
Miami Cancer Institute
Baptist Health South Florida
Miami, Florida
Erica Mayer, MD, MPH, FASCO
Director of Breast Cancer Clinical Research
Breast Oncology Center
Dana-Farber Cancer Institute
Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts
Hope S Rugo, MD
Director, Women’s Cancers Program
Division Chief, Breast Medical Oncology
Professor, Department of Medical Oncology and Therapeutics Research
City of Hope Comprehensive Cancer Center
Duarte, California
Professor Emeritus, UCSF
Priyanka Sharma, MD
Frank B Tyler Professor in Cancer Research
Division of Medical Oncology, Department of Internal Medicine
Co-Program Leader
Drug Discovery, Delivery and Experimental Therapeutics Program
The University of Kansas Cancer Center
Westwood, Kansas
Rebecca Shatsky, MD
Professor of Clinical Medicine
Breast Medical Oncology Team Leader
Director of Breast Cancer Clinical Trials
Director of Inflammatory and Triple Negative Breast Cancer Program
University of California San Diego
Moores Cancer Center
San Diego, California
These activities are supported by educational grants from Biotheranostics Inc, A Hologic Company, Exact Sciences Corporation, Lilly, and Novartis.
Each 1-hour session will include 3 topic modules focused on optimizing treatment for patients with hormone receptor (HR)-positive localized breast cancer. Each event will employ an identical format that will include the following elements:
- Discussion of Steering Committee Members’ Treatment Recommendations
- Review of Available Clinical Research Findings
- Integration of Interactive Audience Q&A Discussion
MODULE 1 Risk Assessment and Genomic Assays in the Management of HR-Positive, HER2-Negative Localized Breast Cancer
- Similarities and differences among available genomic assays
- Clinicopathologic factors affecting the risk of recurrence and the decision to consult a genomic classifier for premenopausal and postmenopausal patients with HR-positive, HER2-negative localized breast cancer
- Design, eligibility criteria and major outcomes from the Phase III TAILORx trial evaluating whether hormone therapy alone is noninferior to hormone therapy with chemotherapy for women with HR-positive, HER2-negative, node-negative localized breast cancer, using the 21-gene Recurrence Score® (RS)
- Design, eligibility criteria and major outcomes from the Phase III RxPONDER trial evaluating the role of chemotherapy for patients with HR-positive, HER2-negative localized breast cancer with 1 to 3 positive lymph nodes and a 21-gene RS of ≤25; optimal use of the 21-gene RS to guide treatment decisions
- Other available datasets with and current clinical utility of various genomic assays in guiding neoadjuvant and adjuvant treatment decision-making for HR-positive, HER2-negative localized breast cancer
- Development, validation and utility of the RSClin educational tool integrating the 21-gene RS and clinicopathologic features to individualize treatment for patients with localized HR-positive, HER2-negative, node-negative infiltrating ductal carcinoma
- Key findings on the use of Breast Cancer Index® to predict the likelihood of benefit from extended-adjuvant systemic therapy for patients with localized breast cancer; current role in clinical decision-making
MODULE 2 Adjuvant CDK4/6 Inhibitors for High-Risk HR-Positive, HER2-Negative Localized Breast Cancer
- Clinical and biological factors in the choice of adjuvant therapy for HR-positive, HER2-negative localized breast cancer; rationale for the addition of CDK4/6 inhibitors to standard adjuvant endocrine therapy
- Extended follow-up from the Phase III monarchE trial evaluating the addition of abemaciclib to standard adjuvant hormonal therapy for patients with high-risk HR-positive, HER2-negative localized breast cancer
- Published efficacy and safety findings with adjuvant ribociclib and endocrine therapy compared to endocrine therapy alone in the NATALEE trial
MODULE 3 Tolerability and Other Practical Considerations with Adjuvant CDK4/6 Inhibitor Therapy
- Available data documenting the spectrum, incidence and severity of common and more serious clinically relevant treatment-emergent adverse events observed with CDK4/6 inhibitors in the adjuvant setting; similarities and differences from experience in the management of metastatic disease
- Optimal dosing of CDK4/6 inhibitors for patients with localized breast cancer; rates of dose reduction, dose delay and treatment discontinuation among patients experiencing toxicities
- Recommendations for prophylaxis, monitoring and management of CDK4/6 inhibitor-associated toxicities for patients with breast cancer undergoing potentially curative therapy
Each session will conclude with a 5-minute Q&A segment
Target Audience
This activity is intended for medical oncologists, breast surgeons, radiation oncologists and other healthcare professionals involved in the diagnosis and treatment of breast cancer.
Learning Objectives
Upon completion of this activity, participants should be able to
- Understand how various clinical and biological factors, such as age and menopausal status, tumor size and grade, and nodal involvement, affect a patient’s risk of disease recurrence, and use this information to personalize the selection of adjuvant systemic therapy for those with newly diagnosed hormone receptor (HR)-positive, HER2-negative breast cancer.
- Consider available clinical trial findings with CDK4/6 inhibitors for localized HR-positive, HER2-negative breast cancer, and identify patients for whom adjuvant treatment with one of these agents would be appropriate.
- Recognize adverse events associated with various CDK4/6 inhibitors, and tailor therapy for patients with HR-positive, HER2-negative localized breast cancer and preexisting medical conditions and relevant comorbidities.
- Develop preventive and emergent strategies to reduce or ameliorate the various toxicities associated with CDK4/6 inhibitors.
- Assess the similarities and differences among the various genomic assays with established prognostic and predictive utility for HR-positive localized breast cancer, and consider available research informing the use of these tests.
CE Credit
CME and ABIM MOC credit information will be provided to each participant at the conclusion of the activity.
Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Credit Designation Statement
Research To Practice designates each live activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
American Board of Internal Medicine (ABIM) — Maintenance of Certification (MOC)
Successful completion of each CME activity, which includes participation in the evaluation component and a post-test, enables the participant to earn up to 1 Medical Knowledge MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for this activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Please note, this program has been specifically designed for the following ABIM specialty: medical oncology.
American Board of Surgery (ABS) — Continuous Certification (CC)
Successful completion of each CME activity, which includes participation in the evaluation component and a post-test, enables the learner to earn up to 1 Medical Knowledge MOC point toward the CME and Self-Assessment requirement(s) of the American Board of Surgery’s Continuous Certification program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABS credit.
Please note, this program has been specifically designed for the following ABS practice area: complex general surgical oncology.
Privacy Policy
Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.
Unlabeled/Unapproved Uses Notice
These educational activities may contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the provider or grantors.
Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
Steering Committee — The following faculty reported relevant financial relationships with ineligible entities:
Dr Brufsky — Consulting Agreements: Agendia Inc, AstraZeneca Pharmaceuticals LP, BriaCell, Celcuity, Daiichi Sankyo Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, Lilly, Merck, Myriad Genetic Laboratories Inc, Novartis, Pfizer Inc, Puma Biotechnology Inc, Sanofi.
Dr Jhaveri — Advisory Committees and Consulting Agreements: Arvinas, AstraZeneca Pharmaceuticals LP, BeOne, Bicycle Therapeutics, Blueprint Medicines, BridgeBio Oncology Therapeutics, ConcertAI, Daiichi Sankyo Inc, Eisai Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, Halda Therapeutics, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Mersana Therapeutics Inc, Natera Inc, Novartis, Olema Oncology, Pfizer Inc, Precede Biosciences, RayzeBio Inc, Relay Therapeutics, Scorpion Therapeutics, Zymeworks Inc; Contracted Research: AstraZeneca Pharmaceuticals LP, Bicycle Therapeutics, Blueprint Medicines, BridgeBio Oncology Therapeutics, Eisai Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Novartis, Pfizer Inc, Puma Biotechnology Inc, RayzeBio Inc, Scorpion Therapeutics, Zymeworks Inc.
Dr Kalinsky — Advisory Committees: AstraZeneca Pharmaceuticals LP, Biotheranostics Inc, A Hologic Company, Daiichi Sankyo Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, Lilly, Menarini Silicon Biosystems, Merck, Mersana Therapeutics Inc, Myovant Sciences, Novartis, Pfizer Inc, ProteinQure, Puma Biotechnology Inc, Regor Therapeutics, Relay Therapeutics, Seagen Inc.
Dr Mahtani — Advisory Committees: AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, Gilead Sciences Inc, Pfizer Inc, Stemline Therapeutics Inc; Consulting Agreements: Agendia Inc, Arvinas, AstraZeneca Pharmaceuticals LP, Biotheranostics Inc, A Hologic Company, Daiichi Sankyo Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, Lilly, Novartis, Pfizer Inc, Puma Biotechnology Inc, Stemline Therapeutics Inc; Contracted Research (Paid to Institution): Gilead Sciences Inc.
Dr Mayer — Consulting Agreements: Aktis Oncology, AstraZeneca Pharmaceuticals LP, Genentech, a member of the Roche Group, Lilly, Novartis.
Dr Rugo — Advisory Committees and Consulting Agreements: BioNTech SE, Bristol Myers Squibb, Helsinn Therapeutics (US) Inc, Napo Pharmaceuticals; Contracted Research (Funding to City of Hope): Bicycle Therapeutics, Genentech, a member of the Roche Group, Stemline Therapeutics Inc; Contracted Research (Funding to Prior Institution, UCSF): Ambrx Inc, AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, Lilly, Merck, Novartis, Pfizer Inc, Stemline Therapeutics Inc.
Dr Sharma — Advisory Committees: AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, Gilead Sciences Inc, Menarini Group, Merck, Novartis, Pfizer Inc, Stemline Therapeutics Inc; Contracted Research: Bristol Myers Squibb, Gilead Sciences Inc, Novartis; Data and Safety Monitoring Boards/Committees: Jazz Pharmaceuticals Inc.
Dr Shatsky — Advisory Committees: AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, Gilead Sciences Inc, Lilly, Merck, Novartis, Pfizer Inc, Stemline Therapeutics Inc; Consulting Agreements: Daiichi Sankyo Inc; Contracted Research: Institutional funding (principal investigator for trials) — Alterome Therapeutics, AstraZeneca Pharmaceuticals LP, BriaCell, Gilead Sciences Inc, Hummingbird Bioscience, Jazz Pharmaceuticals Inc, Mabwell Therapeutics Inc, OBI Pharma Inc, OnKure Therapeutics, Regor Therapeutics, Stemline Therapeutics Inc.
Program Chair
Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: Aadi Bioscience, AbbVie Inc, ADC Therapeutics, Agendia Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Arvinas, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeOne, Biotheranostics Inc, A Hologic Company, Black Diamond Therapeutics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Celcuity, Clovis Oncology, Coherus BioSciences, Corcept Therapeutics Inc, CTI BioPharma, a Sobi Company, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, Exact Sciences Corporation, Exelixis Inc, Genentech, a member of the Roche Group, Genmab US Inc, Geron Corporation, Gilead Sciences Inc, GSK, Helsinn Therapeutics (US) Inc, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Jazz Pharmaceuticals Inc, Johnson & Johnson, Karyopharm Therapeutics, Kite, A Gilead Company, Kura Oncology, Legend Biotech, Lilly, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Mural Oncology Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Nuvalent, Nuvation Bio Inc, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Rigel Pharmaceuticals Inc, R-Pharm US, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Sumitomo Pharma America, Syndax Pharmaceuticals, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, and Tesaro, A GSK Company.
RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS
Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.
Supporters
These activities are supported by educational grants from Biotheranostics Inc, A Hologic Company, Exact Sciences Corporation, Lilly, and Novartis.
|
